ITP: A new regulatory issue!
First published: 04 August 2007
John W. Semple, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8. Tel: 416-864-5534; Fax: 416-864-3053;e-mail:
[email protected] No abstract is available for this article.
References
- 1
Cines DB,
Blanchette VS.
Immune thrombocytopenic purpura.
N Engl J Med
2002; 346: 995–1008.
- 2
Semple JW,
Freedman J.
Mechanisms underlying autoimmunity in hematology.
Drug Discovery Today: Disease Mechanisms
2006; 3: 231–5.
- 3
Olsson B,
Andersson PO,
Jernas M,
et al.
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.
Nat Med
2003; 9: 1123–4.
- 4
Dzionek A,
Fuchs A,
Schmidt P,
et al.
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood.
J Immunol
2000; 165: 6037–46.
- 5
Sakaguchi S.
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.
Annu Rev Immunol
2004; 22: 531–62.
- 6
Banerjee DK,
Dhodapkar MV,
Matayeva E,
Steinman RM,
Dhodapkar KM.
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.
Blood
2006; 108: 2655–61.
- 7
Steinman RM,
Hemmi H.
Dendritic cells: translating innate to adaptive immunity.
Curr Top Microbiol Immunol
2006; 311: 17–58.
- 8
Hsu Nc,
Chung CY,
Horng HC.
Corticosteroid administration depresses circulating dendritic cells in ITP.
Platelets
2004; 15: 451–4.
